8-K: Disc Medicine Announces Positive Financial Results and Clinical Updates, Eyes Accelerated Approval for Bitopertin

Disc Medicine reports strong financial results for 2024 and provides updates on its clinical programs, including plans for an NDA submission for bitopertin in H2 2025.

Summary

• Disc Medicine announced its financial results for the fourth quarter and fiscal year ended December 31, 2024, along with a corporate update.
• The company is targeting an NDA submission for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 through the accelerated approval pathway.
• They are on track to initiate the APOLLO post-marketing confirmatory trial by mid-2025.
• Positive data from the Phase 1b trial of DISC-0974 in patients with anemia of myelofibrosis (MF) was presented at ASH 2024, with initial Phase 2 data expected in H2 2025.
• Positive data from initial cohorts of the Phase 1b study of DISC-0974 in patients with anemia of non-dialysis-dependent chronic kidney disease (NDD-CKD) was presented at ASN Kidney Week 2024, with initial data from the multiple dose portion expected in H2 2025.
• First-in-human data from the Phase 1 trial of DISC-3405 demonstrated proof-of-mechanism, and a Phase 2 study in polycythemia vera (PV) is expected to initiate in H1 2025.
• The company ended 2024 with $490 million in cash, cash equivalents, and marketable securities, further strengthened by a public offering in January 2025, expected to fund operations into 2028.
• Full year 2024 R&D expenses were $96.7 million, compared to $69.3 million in 2023.
• Full year 2024 SG&A expenses were $33.0 million, compared to $21.9 million in 2023.
• Net loss for the full year 2024 was $109.4 million, compared to $76.4 million in 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financials, progress in clinical trials, and a clear path to potential regulatory approval. The company's cash position and pipeline advancements contribute to a favorable sentiment.

Positives

• The company has a strong cash position of $490 million, expected to fund operations into 2028.
• Bitopertin has a potential accelerated approval pathway for EPP.
• Positive clinical data readouts were presented for DISC-0974 in anemias of MF and NDD-CKD.
• DISC-3405 demonstrated proof-of-mechanism in a Phase 1 trial.
• The company completed a $200 million non-dilutive debt financing with Hercules Capital.

Negatives

• The company reported a net loss of $109.4 million for the full year 2024, an increase from $76.4 million in 2023.
• Increased R&D and SG&A expenses contributed to the higher net loss.

Risks

• The company's ability to successfully initiate and complete clinical trials is subject to risk.
• Clinical trial results may not be predictive of future results.
• The company's reliance on the accelerated approval pathway for bitopertin carries regulatory risk.
• The company's ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases is subject to risk.

Future Outlook

Disc Medicine expects its existing cash, cash equivalents, and marketable securities as of December 31, 2024, together with the estimated net proceeds of $243.3 million from its underwritten public offering completed in January 2025, will be sufficient to fund operational plans into 2028.

Management Comments

• 2024 was a transformative year for Disc, marked by the achievement of several milestones, most notably opening the door to a potential accelerated approval for bitopertin based on Phase 2 results linking PPIX reduction to improvement on clinical outcomes in EPP patients, and subsequently gaining alignment on the design of the APOLLO trial as a confirmatory study, said John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc.
• These achievements bring us meaningfully closer to delivering a potentially disease-modifying and life-altering treatment to patients.
• We expect to initiate the APOLLO trial in mid-2025 followed by an NDA submission in the second half of this year and are diligently preparing for the opportunity to bring bitopertin to market.
• In addition, we saw momentum across our portfolio, presenting positive clinical data readouts for each of our clinical programs.
• These latest clinical results strengthen our belief in the potential of our iron homeostasis portfolio assets to address a range of hematological diseases.

Industry Context

Disc Medicine is focused on hematologic diseases, a competitive area with companies like Agios Pharmaceuticals, Global Blood Therapeutics (acquired by Pfizer), and Acceleron Pharma (acquired by Merck) also developing treatments for related conditions. The focus on heme biosynthesis and iron homeostasis pathways differentiates Disc Medicine's approach.

Comparison to Industry Standards

• Disc Medicine's cash runway into 2028 is strong compared to other clinical-stage biopharmaceutical companies, providing financial flexibility.
• The accelerated approval pathway for bitopertin is similar to strategies employed by other companies targeting rare diseases with unmet needs.
• The company's R&D spending is in line with other companies advancing multiple clinical programs.

Stakeholder Impact

• Shareholders: Positive news regarding financial stability and clinical progress.
• Patients: Potential for new treatments for serious hematologic diseases.
• Employees: Job security and growth opportunities due to company's strong financial position.
• Creditors: Low risk due to strong cash position.

Next Steps

• Initiate the APOLLO post-marketing confirmatory trial by mid-2025.
• Submit NDA for bitopertin under accelerated approval pathway in H2 2025.
• Present initial data from the ongoing Phase 2 MF anemia trial and multiple-dose data from the ongoing Phase 1b NDD-CKD trial in H2 2025.
• Initiate a Phase 2 study in PV for DISC-3405 in H1 2025.

Key Dates